Literature DB >> 20299956

Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.

Maria Peñaranda1, Antoni Payeras, Ana Cambra, Joan Mila, Melcior Riera.   

Abstract

This is a randomized trial to compare the immunoglobulin G response and the antibody avidity after two pneumococcal vaccinations, conjugated pneumococcal vaccine (CPV) and polysaccharide pneumococcal vaccine (PPV) 4 weeks after vs. PPV alone in 202 HIV-infected adults. There were no differences in the two strategies, either in the percentage of immunoglobulin G two-fold increase for the CPV included serotypes or immunoglobulin G two-fold increase, reaching the level of 1 microg/ml except for serotype 23F (26% responded after conjugated pneumococcal vaccine + PPV vs. 14% after PPV). No avidity increases were seen in any strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299956     DOI: 10.1097/QAD.0b013e3283389de5

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  14 in total

1.  Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.

Authors:  Indhira De La Rosa; Iona M Munjal; Maria Rodriguez-Barradas; Xiaoying Yu; Liise-Anne Pirofski; Daniel Mendoza
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

Review 2.  Pneumococcal Vaccination Strategies Among HIV-infected Adult Patients: A Review of the Literature.

Authors:  Anna Garmpi; Christos Damaskos; Nikolaos Garmpis; Alexandros Patsouras; Spyridon Savvanis; Nikolaos Gravvanis; Evangelos Diamantis
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

3.  Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  C Quach-Thanh; Ms H Thomas
Journal:  Can Commun Dis Rep       Date:  2013-10-30

4.  Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.

Authors:  Jennifer A Ohtola; Jessica L Saul-McBeth; Anita S Iyer; David J Leggat; Sadik A Khuder; Noor M Khaskhely; Ma Julie Westerink
Journal:  J AIDS Clin Res       Date:  2016-03-14

5.  Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.

Authors:  Ching-Lan Lu; Chien-Ching Hung; Yu-Chung Chuang; Wen-Chun Liu; Chin-Ting Su; Yi-Ching Su; Shu-Fang Chang; Sui-Yuan Chang; Shan-Chwen Chang
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 6.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?

Authors:  Iman Ridda; Daniel M Musher
Journal:  Australas Med J       Date:  2012-04-30

8.  Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.

Authors:  H Schaballie; G Wuyts; D Dillaerts; G Frans; L Moens; M Proesmans; F Vermeulen; K De Boeck; I Meyts; X Bossuyt
Journal:  Clin Exp Immunol       Date:  2016-05-20       Impact factor: 4.330

9.  Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.

Authors:  Jennifer A Ohtola; Noor M Khaskhely; Jessica L Saul-Mcbeth; Anita S Iyer; David J Leggat; Sadik A Khuder; M A Julie Westerink
Journal:  Vaccine       Date:  2015-12-18       Impact factor: 3.641

Review 10.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.